OBJECTIVES: To evaluate the health and economic benefits of different screening and vaccination strategies against cervical cancer in the Philippines. METHODS:   A cost-utility analysis was conducted using an existing semi-Markov model to evaluate different screening (i.e. Pap smear, visual acetic acid) and vaccination strategies against HPV infection implemented alone or as part of a combination strategy at different coverage scenarios. From a health system perspective, the researchers ran the model using country-specific epidemiologic, cost and clinical parameters. Sensitivity analysis was performed for vaccine efficacy, duration of protection and costs of vaccination, screening and treatment. RESULTS: Across all coverage scenarios, VIA has been shown to be a dominant and cost-saving strategy with ICERs ranging from -Php 191,099 to Php 61,058.73 per QALY gained. Due to its high cost in the Philippines, Pap smear was found to be not cost-effective. At a cost of Php 2,400 per vaccinated girl, vaccination was found to be cost-effective at a threshold of 1 GDP per capita with the most favorable assumption of providing lifelong immunity against high-risk oncogenic HPV types 16/18.  The highest incremental QALY gain was achieved with 80% coverage of the combined strategy of VIA at 35 to 45 years old done every five years following vaccination at 11 years of age with an ICER of Php 33,126. HPV vaccination becomes less cost-effective when vaccine protection lasts for less than 15 years. CONCLUSIONS: High VIA coverage targeting women aged 35-45 years old at five-year intervals is the most efficient and cost-saving strategy in reducing cervical cancer burden in the Philippines. Adding a vaccination program among 11-year old girls at a cost of Php 2,400 per vaccinated child is potentially cost-effective with the most favourable assumption that the vaccines provide lifelong immunity against HPV 16/18.